ABSTRACT
Background: Respiratory diseases account for leading cause of death worldwide. Literature reveal respiratory research is inadequately funded despite the global mortality and morbidity. Studies and analysis have also identified disease groups get funded disproportionately. Aim(s): To explore differential funding within respiratory research funding in UK and Europe and identify volume of funding for COVID-19. Methodology: A review of research funding data for respiratory diseases (2012-2022) undertaken. We reviewed funding from UK & European funding bodies. Funding was expressed in million Euros. The respiratory disease groups identified as in table 1. Result(s): 288 studies identified and asthma had the highest number of studies, with the second highest funding allocation. Interstingly, the highest funding was Tuberculosis, the least for sleep apneoa. COVID-19 related research with 10% of the funding. Diseases with highest mortality like Lung cancer, COPD and ILD received less than 17% of the funding. COVID-19 has attracted 10% of the funding recently. Table1, shows individual studies and funding allocation. Conclusion(s): We observed heterogeneity in the funding allocation for respiratory disease groups and mismatch with mortality caused by the respiratory subgroups. Unsurprisingly, there seems to have been increase in COVID research funding recently.